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patients compared to non-NDRI patients indicate that
NDRI results in statistically signiﬁcant increases in both
direct and indirect costs to the employer.
PRK5
ANALYSIS OF COMORBIDITY, HOSPITAL
UTILIZATION AND COST OF OVERACTIVE
BLADDER IN A CALIFORNIA MEDICAID
PROGRAM—A CASE-CONTROL STUDY
Yu YF, Yu AP,Ahn J, Nichol MB
University of Southern California, Los Angeles, CA, USA
OBJECTIVES: To explore the possible comorbidities
associated with Overactive Bladder (OAB), and to esti-
mate the resource utilization pattern and cost of OAB 
in a Medicaid population. METHODS: A retrospective
case-control matching study was performed. Five thou-
sand ﬁve hundred seven continuously enrolled Medi-Cal
patients who were diagnosed with OAB and received
OAB prescriptions from 1999 to 2001 were 1 :2 matched
based on age, gender, race, and residence county. Annual
hospital utilization and cost were calculated for both
OAB and matched control cohorts, and prevalence ratios
(PR, OAB over control) for 34 ICD-9 based comorbidity
measures from AHRQ were examined. RESULTS: Out of
34 comorbidities, 13 occurred in OAB patients at least
twice as much as in general Medicaid population: paral-
ysis (PR = 10.46), urinary track infection (UTI, PR =
3.74), other neurological (PR = 2.79), peripheral vascu-
lar disorder (PR = 2.42), valvular disease (PR = 2.32),
arrhythmias (PR = 2.31), atopic dermatitis (PR = 2.19),
blood loss anemia (PR = 2.14), depression (PR = 2.10),
pulmonary circulation disorder (PR = 2.10), hypothy-
roidism (PR = 2.08), peptic ulcer disease including bleed-
ing (PR = 2.08), and deﬁciency anemias (PR = 2.05).
Among these diagnoses, obesity, UTI, dermatitis and
depression are known comorbidities related to OAB.
OAB patients had much higher annual resource utiliza-
tion than the matched control group: physician ofﬁce
encounters (27.39 vs. 2.70, P < 0.0001), and an emer-
gency room visits (0.26 vs. 0.04, P < 0.0001). OAB
patients had approximately two-fold higher costs than the
control cohort for pharmacy and medical services:
$3319.85 vs. $1560.06 (P < 0.0001), $4754.86 vs.
$2592.68 (P < 0.0001). CONCLUSIONS: OAB patients
who received drug treatment incurred a heavy economic
and resource burden to the California Medicaid program.
Comorbid conditions were much more prevalent in the
OAB cohort than in the general Medicaid population.
PRK6
A RETROSPECTIVE CLAIMS ANALYSIS OF THE
DIRECT COSTS OF STRESS URINARY
INCONTINENCE
Long S1, Kinchen K2, Orsini LS1, Crown W1, Swindle R2
1The Medstat Group, Inc, Cambridge, MA, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA
OBJECTIVE: To evaluate direct expenditures associated
with urinary incontinence and overall medical expendi-
tures incurred by women diagnosed with stress urinary
incontinence (SUI). METHODS: This is a Retrospective
analysis of administrative claims data. We identiﬁed
women with a diagnosis of SUI in 1996–1999 and no
stress, urge or mixed urinary incontinence diagnoses in
the prior year. We compared total expenditures as well 
as urinary-incontinence-related expenditures for the year
before and after the initial SUI diagnosis. We also com-
pared expenditures for SUI patients receiving surgical
treatment to those who did not. RESULTS: Patients who
met eligibility criteria totaled 8126. Mean annual total
expenditures and UI-related expenditures for all SUI
patients in the year following initial SUI diagnosis were
$9147 (SD $12,434) and $1,382 (SD $2,758) respectively
(15% of total expenditures). The predicted annual total
expenditures and UI-related expenditures for surgical
patients were $13,081 (SD $5,015) and $3,905 (SD
$1134) (30% of total expenditures). Among women with
no comorbid urinary diagnoses, approximately 10%
($733; SD $1,992) of total mean regression-adjusted
annual expenditures ($7,075; SD $12,594) were attrib-
utable to UI. Predicted total expenditures for surgery
patients without comorbid urinary diagnoses were
$13,018 (SD $6,234), 31% of which ($4,056; SD $1,519)
were for UI-related costs. CONCLUSIONS: After diag-
nosis, annual expenditures for patients were roughly
twice that in the year prior to diagnosis. Multivariate
analysis suggests that in the year after SUI diagnosis, UI
treatment costs represented approximately 10–15% of
total expenditures for all SUI patients, and 30–31% of
total expenditures for the subset of surgically-treated
patients.
PRK7
COMPARISON OF TACROLIMUS WITH
CYCLOSPORIN IN KIDNEY TRANSPLANTATION:
COST-MINIMISATION AND COST-
EFFECTIVENESS ANALYSES
Klein WH1, McKechnie T2, Schindler TM3
1PharmaExperience, Neubiberg, Germany; 2The Lewin Group
Quintiles UK Ltd, Bracknell, United Kingdom; 3Fujisawa GmbH,
Munich, Germany
OBJECTIVES: The costs associated with kidney trans-
plantation are substantial, not only because of trans-
plantation surgery but also due to the life-long need for
immunosuppressive medication to prevent graft rejection.
We analyzed the economic consequences of the use of 
the two baseline immunosuppressants, tacrolimus (Tac)
and cyclosporin (CyA), currently administered in clinical
practice. METHODS: A retrospective economic analysis
was performed from a hospital perspective in Italy, Spain,
and Germany. The analysis was conducted on the ITT-
population comprising 557 patients from 7 European
countries. Thus, the clinical and medical resource infor-
mation for the pharmacoeconomic analysis was pooled
multi-country data, the cost data was country speciﬁc.
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Costs were calculated on the actual resources used by
each patient and assigned to the treatment group to which
the patient was randomized. Direct medical resource use
data was costed over six months post transplantation. A
local health economist collected cost information from
published sources and personal interviews with clinicians.
Costs were collected on study drug, concomitant med-
ication, hospitalization, dialysis, and rejection episodes.
To explore the impact of any variability of costs, a one-
way sensitivity analysis was conducted. RESULTS: Six
months after transplantation, patient survival was 99.3%
(Tac) and 98.5% (CyA), p = 0.366; graft survival was
94.6% (Tac) and 91.9% (CyA), p = 0.139. The incidence
of acute graft rejection was 32.5% (Tac) and 51.3%
(CyA), p < 0.0001. Cost-minimization analysis revealed
savings for tacrolimus (per patient) of Euro 583–1874 
for surviving patients, and Euro 781–2305 for patients
with functioning grafts. Tacrolimus was cost-effective for
patients with rejection-free grafts; savings per patient
were Euro 4627–9919. The tacrolimus group consistently
had lower total costs than the cyclosporin group. The cost
advantages for tacrolimus were a result of lower overall
hospitalization costs and lower incidences of dialysis 
and graft rejection. CONCLUSION: A sensitivity analy-
sis regarding the main cost drivers (hospitalization, study
drug, and concomitant medication) generally conﬁrmed
the robustness of this ﬁnding across all three countries.
PRK8
COSTS AND CLINICAL CONSEQUENCES OF
ALFUZOSIN AND DOXAZOZIN IN BENIGN
PROSTATIC HYPERPLASIA IN UKRAINE
Zaliska O, Zchuravchak A
Lviv Medical University, Lviv, Ukraine
OBJECTIVE: Randomized controlled clinical trials have
demonstrated, that alfuzosin (dalfaz R) is comparable to
doxazosin (cardura) in benign prostatic hyperplasia. We
compare the costs and clinical consequences of alfuzosin
vs doxazosin from the perspective of public health care
in Ukraine. Both drugs provide long-lasting relief of
symptoms. METHODS: We compared the rates of PSA
assay, of prostate volume, of while urinary ﬂow (Qmax).
Patients ﬁlled in both the generic IPSS. To calculate the
drug-acquisition costs. RESULTS: A total of 106 patients
(54 alfuzosin, 52 doxazosin) were treated in 6 months.
The mean age of patients was 63.7 years. Relief was seen
as early as one week after the initiation of therapy. We
compared the rates at 1, 3, and 6 months; the prostate
volume decreased by 18% and 19% in the doxazosin and
alfuzosin groups, respectively, while urinary ﬂow (Qmax)
increased by 28 to 29%. The mean percent change in IPSS
was 39.8% (p < 0.05). Overall symptoms improved in
two groups. The direct costs of alfuzosin were 910.0
UAH vs doxazosin 714.1 (1USD = 5.3 UAH) per one
patient. The total cost of 100 patients treated with dox-
azosin were decrease by 27.4% vs alfuzosin. CONCLU-
SIONS: There was no difference in the clinical
consequences of doxazosin vs alfuzosin treatment. Our
study showed that the treatment with doxazosin may
offer economic advantages over alfuzosin, the results 
may provide a basis for creation of formulary system in
Ukraine.
PRK9
COST-EFFECTIVENESS OF TAMSULOSIN,
DOXAZOSIN AND TERAZOSIN IN THE
TREATMENT OF BENIGN PROSTATIC
HYPERPLASIA
Ohsfeldt RL1, Kreder KJ1, Klein R2, Chrischilles EC1
1University of Iowa, Iowa City, IA, USA; 2Medical Decision
Modeling, Inc, Indianapolis, IN, USA
OBJECTIVE: To evaluate the cost-effectiveness of 
tamsulosin, doxazosin or terazosin as initial treatments 
for moderate benign prostatic hyperplasia (BPH).
METHODS: A decision analytic model is used to project
the costs and effectiveness of treatment at 6-month inter-
vals over three years following initiation of therapy with
tamsulosin, doxazosin or terazosin. Patients initially
treated with doxazosin or terazosin who discontinue due
to hypotensive events are switched to tamsulosin. Finas-
teride is added in the event of treatment failure not related
to adverse events. Medical treatment failures transition 
to transurethral resection of the prostate (TURP) and, if
needed, a second TURP. Values for treatment failure rates
and clinical event cost parameters are derived from the
literature. Only direct medical costs are included and are
discounted by 3% per year. Effectiveness is measured as
successful medical treatment (without TURP) over three
years. RESULTS: In the reference case, discounted BPH-
related total direct medical costs over 3 years are $3715,
$3756, and $3992 for generic terazosin, generic doxa-
zosin, and tamsulosin, respectively. Estimated medical
treatment success rates at 3 years are 72.41% for tamsu-
losin, 69.62% for terazosin and 69.28% for doxazosin.
The incremental cost for tamsulosin vs. terazosin is $278,
which yields an incremental cost-effectiveness ratio of
$9964 per success. Decision model results are sensitive to
parameter values for treatment efﬁcacy, drug costs, dis-
continuation rates, and dosing frequency. CONCLU-
SION: As an initial medical therapy for moderate BPH,
tamsulosin is more effective than generic terazosin or
doxazosin, with an incremental cost of about $93 per
year or about $7.75 per month. From a payer’s perspec-
tive, with differential generic/brand patient co-pays of
$8/month or more, tamsulosin is cost saving.
PRK10
COST-MINIMISATION ANALYSIS AND
ACCEPTANCE OF SELF-INJECTING
SUBCUTANEOUSLY R-HUEPO WITH RECO-
PEN® FOR MANAGEMENT OF ANAEMIA IN A
POPULATION OF FRENCH ADULT PATIENTS
ON DIALYSIS
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